

for HEMLIBRA®

(emicizumab-kxwh)

SUBMIT ONLY REQUESTED DOCUMENTS

Required field (*) M-US-00006693(v1.0) 08/20

Step 1 Patient Information

*First name: _____ *Last name: _____
 *Date of birth (MM/DD/YYYY): ____ / ____ / ____ Gender: Male Female
 Street: _____ Apt: _____
 City: _____ *State: _____ ZIP: _____
 Home phone: (____) ____ - ____ Cell phone: (____) ____ - ____ Do not contact patient
 Email: _____ Preferred language: English Spanish Other: _____
 Alternate contact name: _____ Relationship: _____ Alt. phone: (____) ____ - ____

Step 2 Insurance Information Is the patient insured? Yes No

If patient is uninsured, please complete the Genentech Patient Foundation Enrollment Form or call (888) 941-3331 for assistance. If insured, please fill out the information below or attach a copy of the patient's insurance cards.

Primary Insurance		Secondary Insurance
Insurance name		
Subscriber name (if not patient)		
Subscriber/Policy ID #		
Group #		
Insurance phone		

Step 3 Prescription Information

Patient weight:		Please specify quantity of each applicable vial	Directions	Refills
Initial dose	<input type="checkbox"/> 3-mg/kg, ____ mg/kg	____ 30-mg/mL, ____ 60-mg/0.4-mL, ____ 105-mg/0.7-mL, ____ 150-mg/mL		
Subsequent dose	<input type="checkbox"/> 1.5-mg/kg, <input type="checkbox"/> 3-mg/kg, <input type="checkbox"/> 6-mg/kg, ____ mg/kg	____ 30-mg/mL, ____ 60-mg/0.4-mL, ____ 105-mg/0.7-mL, ____ 150-mg/mL		

Preferred specialty pharmacy: _____ Onsite pharmacy: _____

Step 4 Diagnosis and Clinical Information

*To the highest level of specificity, provide primary diagnosis code: _____ Does your patient have Hemophilia A With inhibitors? or Without inhibitors?
 Has the patient started prescribed HEMLIBRA® (emicizumab-kxwh)? Yes No
 Has it been 12 months or more since the patient's last HEMLIBRA injection? Yes No

Step 5 Prescriber Information


*First name: _____ *Last name: _____
 *Practice name: _____
 *Street: _____ Suite: _____ *City: _____
 *State: _____ *ZIP: _____ Prescriber tax ID #: _____
 Prescriber NPI† #: _____ Group NPI† #: _____
 Office contact: _____ Contact phone: (____) ____ - ____ Contact fax: (____) ____ - ____

Step 6 HEMLIBRA Starter Request (signature required)

I approve the dispensing of up to 2 free 30-day supplies of HEMLIBRA to my patient if they experience an insurance coverage delay and otherwise meet eligibility criteria. For full eligibility criteria, please speak to your HEMLIBRA representative.

Step 7 Health Care Provider Certification

By submitting this form, I certify: (a) The above therapy is medically necessary for this patient and the treatment decision has been made by the prescribing physician. (b) If the indication for which this Genentech product is being prescribed to treat is not listed in the FDA-approved label, the prescriber is prescribing the medication for an "unapproved" use, meaning that the FDA has not approved the efficacy, dosage amount or safety of this medication for such a use. (c) The provider's office received the authorization to release the information above and other protected health information (as defined by the Health Insurance Portability and Accountability Act of 1996 [HIPAA]) to Genentech, Inc., Genentech Access Solutions, the contracted dispensing pharmacy, or other contractors for the purpose of requesting reimbursement support, assisting in initiating or continuing therapy, as a break in treatment would negatively impact the patient's therapeutic outcome. (d) The provider's office will not attempt to seek reimbursement for free product provided to the patient. (e) The services requested on behalf of the patient may include benefits investigation (BI), prior authorization (PA), and appeals support, co-pay card and co-pay assistance foundation referral. (f) **No action on these services will be taken until the patient consent document has been received.**

 Sign, date & fax to (877) 886-5629 *Prescriber's Signature: _____ *Date: ____ / ____ / ____
 (Original or stamped signature required)

†National Provider Identifier.

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.

The Access Solutions logo is a registered trademark of Genentech, Inc.

© 2020 Genentech USA, Inc. So. San Francisco, CA All rights reserved.